Cocrystal Pharma (COCP)Director bought ~$71K

~$71K

Approx. value · 75K sh @ $0.9412

1.98M

Holds after · shares reported

Traded

Aug 3, 2026

Filed

Aug 5, 2026

The story around this disclosure

Every dated public record OQRO holds about the company from 60 days before to 120 days after, oldest first. It shows what was going on; none of it is a stated reason for the trade.

1. Jun 3, 2026Company filing · Form 8-K · Executive changeChanged a top executive or board member“On June 3, 2026, the Board of Directors (the “Board”) of Cocrystal Pharma, Inc. (the “Company”) appointed James Sapirstein as the Chief Executive Officer of the Company, effective immediately, pursuant to the terms of an employment offer letter (the “Offer Letter”).”
2. Jul 31, 2026Company filing · Form 8-K · Material agreement, Unregistered sharesSigned an important agreement, and sold new shares without registering them (and 1 more item)
3. Aug 3, 2026 · this disclosureInsider · 9 days before an 8-KDirector purchased ~$71K of COCP shares in the open market

What came next

1. Aug 5, 2026Insider · 7 days before an 8-KDirector purchased ~$9.8K of COCP shares in the open market
2. Aug 12, 2026Company filing · Form 8-K · Executive changeChanged a top executive or board member“On August 12, 2026, the Board of Directors (the “Board”) of Cocrystal Pharma, Inc. (the “Company”) appointed Carol L. Brosgart as a director of the Company, effective immediately.”

How to read SEC Form 4

Form 4 is the filing that officers, directors and owners of more than 10% of a US-listed company must send to the SEC within two business days after they buy, sell or otherwise change their holding of the company's stock.

Full guide: What is an SEC Form 4?

What else is on file for Cocrystal Pharma

For Cocrystal Pharma, OQRO holds 2 insider filings (SEC Form 4 or Form 144) dated in the last 90 days.

These are records OQRO holds, counted by their date, not a measure of how much trading took place. Routine paperwork such as option exercises and tax withholding is left out. Everything for the company is on its COCP page.

Other recent filings by FROST PHILLIP MD ET AL, Director

• SEC Form 4 at Cocrystal Pharma (COCP)Aug 6, 2026
• SEC Form 4 at Cocrystal Pharma (COCP)Feb 25, 2026
• SEC Form 4 at Cocrystal Pharma (COCP)Feb 9, 2026
• SEC Form 4 at Cocrystal Pharma (COCP)Jan 2, 2026
• SEC Form 4 at Cocrystal Pharma (COCP)Dec 31, 2025

The full history of FROST PHILLIP MD ET AL, Director is on the profile page.

How this filing works

• SEC Form 4
• Open-market purchase
• Rule 10b5-1 trading plans

Other disclosures at Cocrystal Pharma

• SEC Form 4Aug 6, 2026
• SEC Form 4Feb 25, 2026
• SEC Form 4Feb 9, 2026
• SEC Form 4Jan 2, 2026
• SEC Form 4Dec 31, 2025
• SEC Form 4Dec 29, 2025

Everything OQRO holds on this company is on its COCP page.